Undiagnosed pulmonary TB and COVID in adults dying at home in a high TB burden setting, before and during pandemic COVID-19: an autopsy study.

BACKGROUND: Missing or undiagnosed patients with TB or COVID-19 are of concern. Identifying both infections in patients with no diagnosis prior to death contributes to understanding burdens of disease. To confirm reports of global reduction in TB incidence a 2012 autopsy study of adults dying at home of natural causes, in a high TB burden setting was repeated, including SARS-CoV-2 assessments after the first COVID-19 surge in South Africa. METHODS: Adult decedents who died at home with insufficient information to determine cause of death, no recent hospitalisation, and no current antemortem TB or COVID-19 diagnosis were identified between March 2019 and October 2020 with a 4 month halt during lockdown. A standardised verbal autopsy followed by minimally-invasive needle autopsy (MIA) was performed. Biopsies were taken for histopathology from liver, bilateral brain and lung; bronchoalveolar lavage was collected for Xpert (MTB/RIF) and mycobacterial culture, and blood for HIV polymerase chain reaction (PCR) testing. After the start of the COVID-19 pandemic, a nasopharyngeal swab and lung tissue were subjected to SARS-CoV-2 PCR testing. RESULTS: Sixty-six MIA were completed, 25 men and 41 women, overall median age 60 years. 68.2% had antemortem respiratory symptoms and 30.3% were people with HIV (PWH). Overall, TB was diagnosed in 11/66 (16.7%) and 14/41 (34.1%) in the COVID-19 pandemic were SARS-CoV-2 positive. CONCLUSION: Undiagnosed TB in adults dying at home has apparently decreased but remains unacceptably high. Forty percent of decedents had undiagnosed COVID-19 suggest estimates of excess deaths may underestimate the impact of SARS-CoV-2 on mortality.

Underdiagnosis of iron deficiency anaemia in HIV-infected individuals: a pilot study using soluble transferrin receptors and intensive bone marrow iron stores to improve the diagnosis.

AIM: We compared soluble transferrin receptors (sTfR), serum ferritin, mean cell volume (MCV) of red cells and the sTfR-ferritin index with the intensive method bone marrow trephine (BMT) iron stores in the diagnosis of iron deficiency anaemia (IDA) in Human Immunodeficiency Virus (HIV)-positive hospitalised participants. METHODS: In this cross-sectional study, we recruited hospitalised HIV-positive and coronavirus of 2019 (COVID-19)-negative adults with anaemia who required a bone marrow examination as part of their diagnostic workup. We measured the full blood count, ferritin, sTfR and assessed iron using the intensive method in Haemotoxylin and Eosin (H&E)-stained BMT core biopsies of consenting participants. RESULTS: Of the 60 enrolled participants, 57 were evaluable. Thirteen (22.80%) had IDA on H&E BMT iron stores assessment, and 44 (77.19%) had anaemia of chronic diseases (ACD). The sTfR and the sTfR-ferritin index had sensitivities of 61.54% and 53.85%, respectively, for IDA diagnosis. The sensitivity and specificity of ferritin was 7.69% and 92.31%, respectively. The sTfR and sTfR-ferritin index's diagnostic specificity was relatively low at 46.15% and 38.46%, respectively. CONCLUSION: In this pilot study in HIV-positive participants, the prevalence of iron deficiency using the BMT assessment was low. Both the sTfR and the sTfR-ferritin index had a better quantitative correlation to bone marrow iron stores when compared with the MCV and ferritin and, may be more accurate surrogate markers of IDA.